Table 1. Demographic and baseline characteristics (randomized population).
| Vildagliptin 100 mg/day + nateglinide 270 mg/day (n = 17) | Vildagliptin 100 mg/day (n = 19) | |
|---|---|---|
| Age (years)† | 66.3 ± 10.0 | 63.0 ± 13.2 |
| <65‡ | 8 (47.1) | 9 (47.4) |
| ≥65‡ | 9 (52.9) | 10 (52.6) |
| Sex‡ | ||
| Males | 10 (58.8) | 15 (78.9) |
| Females | 7 (41.2) | 4 (21.1) |
| Body mass index (kg/m2†) | 25.0 ± 4.1 | 24.7 ± 2.6 |
| BMI <25 kg/m2‡ | 10 (58.8) | 10 (52.6) |
| BMI ≥25 kg/m2‡ | 7 (41.2) | 9 (47.4) |
| HbA1c (%)† | 7.6 ± 0.6 | 7.5 ± 0.6 |
| HbA1c ≤7‡ | 5 (29.4) | 4 (21.1) |
| HbA1c >7 to ≤8‡ | 8 (47.1) | 12 (63.2) |
| HbA1c >8‡ | 4 (23.5) | 3 (15.8) |
| Fasting plasma glucose (mmol/L)† | 8.44 ± 1.56 | 8.45 ± 1.48 |
| Fasting plasma insulin (pmol/L)† | 7.1 ± 4.0 | 7.4 ± 6.0 |
| Disease duration (years)† | 11.8 ± 5.6 | 11.6 ± 9.0 |
| Systolic blood pressure (mmHg)† | 140.8 ± 17.1 | 134.5 ± 13.5 |
| Diastolic blood pressure (mmHg)† | 82.1 ± 11.0 | 77.7 ± 11.2 |
| Medications (n)‡ | ||
| Metformin | 6 (35.2) | 4 (21.1) |
| Pioglitazone | 4 (23.5) | 1 (5.3) |
| Calcium‐channel blockers | 4 (23.5) | 5 (26.3) |
| ARB, ACEi | 6 (35.2) | 7 (36.8) |
| Diuretics | 1 (5.9) | 1 (5.3) |
| β‐Blockers | 0 (0) | 3 (15.8) |
| α‐Blockers | 0 (0) | 2 (10.5) |
| Statins | 9 (52.9) | 9 (47.4) |
| Fibrates | 0 (0) | 1 (5.3) |
| Ezetimibe | 1 (5.9) | 1 (5.3) |
| Anti‐platelet agents | 4 (23.5) | 4 (21.1) |
†Values are mean ± standard deviation.‡Values numbers of patients or percentages. ACE, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II type 2 receptor antagonist; BMI, body mass index; HbA1c, glycated hemoglobin.